带状疱疹疫苗Shingrix创造了8.33亿英镑的收入,超过了预期的8.29亿英镑。葛兰素史克重申了其2023年的业绩指引。今年2月,葛兰素史克预计,按固定汇率计算,2023年的销售额将同比增长6%至8%,调整后的营业利润将同比增长10%至12%。葛兰素史克周三表示,预计今年上半年调整后的营业利润增长率将有所下降,下半年将有所...
带状疱疹疫苗Shingrix创造了8.33亿英镑的收入,超过了预期的8.29亿英镑。 葛兰素史克重申了其2023年的业绩指引。 今年2月,葛兰素史克预计,按固定汇率计算,2023年的销售额将同比增长6%至8%,调整后的营业利润将同比增长10%至12%。 葛兰素史克周三表示,预计今年上半年调整后的营业利润增长率将有所下降,下半年将有所上升,...
4/26/2023 Q1 2023 $0.85 $0.90 +$0.05 $0.90 $8.55 billion $8.45 billion 2/1/2023 Q4 2022 $0.59 $0.64 +$0.05 $0.36 $8.30 billion $8.66 billion Get the Latest News and Ratings for GSK and Related Stocks Enter your email address below to receive the latest news and analysts' rating...
带状疱疹疫苗Shingrix创造了8.33亿英镑的收入,超过了预期的8.29亿英镑。 葛兰素史克重申了其2023年的业绩指引。 今年2月,葛兰素史克预计,按固定汇率计算,2023年的销售额将同比增长6%至8%,调整后的营业利润将同比增长10%至12%。 葛兰素史克周三表示,预计今年上半年调整后的营业利润增长率将有所下降,下半年将有所上升,...
Q1 2023 results announcement (PDF, 1,019.3KB) Q1 2023 performance highlights Sales performance reflected lower COVID-19 solutions sales versus Q1 2022. Excluding COVID-19 solutions, sales grew +10% CER with strong performance across Vaccines, Specialty and General Medicines Key growth drivers includ...
Q2 2023 26 Jul 2023 17 Aug 2023 18 Aug 2023 20 Sep 2023 12 Oct 2023 Ordinary: 14pADR: $0.3435320 Q1 2023 26 Apr 2023 18 May 2023 19 May 2023 21 Jun 2023 13 Jul 2023 Ordinary: 14pADR: $0.3609438 Q4 2022 1 Feb 2023 23 Feb 2023 24 Feb 2023 21 March ...
GBP+8.8%+8.8%-3.2%-3.2%+640.7%+640.7%+95.2%+95.2%+27.5%+27.5%+35.5%+35.5%-15.3%-15.3%-58.0%-58.0%-19.2%-19.2%EPS ActualEPS Estimate2022 Q12022 Q22022 Q32022 Q42023 Q12023 Q22023 Q32023 Q42024 Q12024 Q22024 Q32024 Q40.001.002.003...
葛兰素史克(GSK.US)Q1业绩超预期 重申2023年指引 智通财经 04-26 15:28 116 0 公告1st Quarter Results 葛兰素史克(UK)资讯 04-26 15:03 120 0 公告EMA validates Jemperli filing for new indication 葛兰素史克(UK)资讯 04-25 15:08 127 0
are subject to risks and uncertainties that may cause actual results to differ materially from those projected. Such factors include, but are not limited to, those described under Item 3.D 'Risk factors” in the company's Annual Report on Form 20-F for 2022, and Q1 Results for 2023 and ...
Discover our latest financial performance announcement and search for historical quarterly results materials